| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/18/2009 | WO2009074674A2 Trisubstituted piperidines as renin inhibitors |
| 06/18/2009 | WO2009074519A1 Combinations of pyrazolyl or isoxazolyl p2x7 modulators with further therapeutic agents |
| 06/18/2009 | WO2009074498A1 Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate |
| 06/18/2009 | WO2009074249A1 Oxazolidinones for the treatment and/or prophylaxis of heart failure |
| 06/18/2009 | WO2009073944A1 USE OF PYRIDOXINE α-HYDROXYISOCAPROATE TO REDUCE METABOLIC ACIDOSIS AND AMMONIA ACCUMULATION |
| 06/18/2009 | WO2009053748A3 Novel crystalline forms |
| 06/18/2009 | WO2009046864A3 Use of the human pancreatic polypeptide as a therapeutic agent |
| 06/18/2009 | WO2009046847A3 Use of peptide ll-37 as a therapeutic agent |
| 06/18/2009 | WO2009046846A3 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 06/18/2009 | WO2009043476A3 Neuromedin s as a therapeutic agent |
| 06/18/2009 | WO2009043448A3 Neuromedin u-25 and neuromedin s as therapeutic agents |
| 06/18/2009 | WO2009043440A3 Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent |
| 06/18/2009 | WO2009043170A8 Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors |
| 06/18/2009 | WO2009038385A3 Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same |
| 06/18/2009 | WO2009016081A3 Benzoind0l-2-one derivatives for use in therapy |
| 06/18/2009 | WO2008156831A3 Renin inhibitors |
| 06/18/2009 | WO2008156816A3 Renin inhibitors |
| 06/18/2009 | US20090156862 Highly pure (R,R)-formoterol L-tartrate composition obtained by crystallizing a first polymorph of (R,R)-formoterol L-tartrate from aqueous isopropyl alcohol |
| 06/18/2009 | US20090156821 Quinazoline compounds |
| 06/18/2009 | US20090156803 Condensed furan compounds |
| 06/18/2009 | US20090156685 (r)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity |
| 06/18/2009 | US20090156681 Compounds for the treatment of metabolic disorders |
| 06/18/2009 | US20090156675 Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
| 06/18/2009 | US20090156665 Compositions Comprising Flavonoids and Toctrienols and Methods Thereof |
| 06/18/2009 | US20090156663 Functional Foods Comprising Flavonoids and Tocotrienols and Methods Thereof |
| 06/18/2009 | US20090156641 Inhibition of cyclooxygenase-2 activity |
| 06/18/2009 | US20090156640 Nociceptin analogs |
| 06/18/2009 | US20090156637 Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress |
| 06/18/2009 | US20090156633 Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity |
| 06/18/2009 | US20090156632 Dosage regimen for prasugrel |
| 06/18/2009 | US20090156623 N-aryl piperidine substituted biphenylcarboxamides |
| 06/18/2009 | US20090156622 2,4-pyrimidinediamine compounds and their uses |
| 06/18/2009 | US20090156620 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| 06/18/2009 | US20090156618 1-(1- (2-Ethoxyethyl)-3-Ethyl-7-(4-Methylpyridin-2-Ylamino) - 1H-Pyrazolo [4,3-D] Pyrimidin-5-YL) Piperidine-4-Carboxylic acid and salts thereof |
| 06/18/2009 | US20090156612 Substituted imidazole compound and use thereof |
| 06/18/2009 | US20090156599 Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
| 06/18/2009 | US20090156597 Novel Compounds |
| 06/18/2009 | US20090156585 Organic compounds |
| 06/18/2009 | US20090156579 Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension |
| 06/18/2009 | US20090156574 N-(4-(5-Butyl-2-methoxyphenyl)-1,3-thiazol-2-yl)-4-((4-oxopiperidin-1-yl)carbonyl)benzamide; antiinflammatory, anticarcinogenic, antidiabetic, analgesic agents |
| 06/18/2009 | US20090156529 RNAi Inhibition of Alpha-ENaC Expression |
| 06/18/2009 | US20090156507 Cell permeable conjugates of peptides for inhibition of protein kinases |
| 06/18/2009 | US20090156502 Vascular Leak Syndrome; polypeptide toxophore from a DT; has cytotoxicity comparable to that of a DT molecule |
| 06/18/2009 | US20090156493 Urocortin-iii and uses thereof |
| 06/18/2009 | US20090156488 Use of neuregulin for organ preservation |
| 06/18/2009 | US20090156487 Infant nutritional compositions for preventing obesity |
| 06/18/2009 | US20090155906 Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line |
| 06/18/2009 | US20090155897 Glycoprotein vi fusion proteins |
| 06/18/2009 | US20090155350 Chlamydia antigens and protein vaccine |
| 06/18/2009 | US20090155344 Preparation and application of biodegradable-material-made microsphere vascular embolus containing liposome-encapsulated cytokines |
| 06/18/2009 | US20090155336 Neuromodulatory methods for treating pulmonary disorders |
| 06/18/2009 | US20090155281 Methods of using antibodies that bind both bcma and taci |
| 06/18/2009 | US20090155258 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 06/18/2009 | US20090155240 Dichloroacetate in combination with clinically high levels of cardioprotective or hemodynamic drugs |
| 06/18/2009 | US20090155239 Novel Protease, Microorganism Producing the Same, and Application Thereof |
| 06/18/2009 | US20090155227 Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
| 06/18/2009 | US20090155225 Uses and isolation of very small of embryonic-like (vsel) stem cells |
| 06/18/2009 | US20090155205 HUMAN ANTIBODIES THAT BIND HUMAN TNFa |
| 06/18/2009 | DE102005023666B4 Verwendung von Murmeltieröl zur Behandlung von Akne vulgaris, Akne rosacea, Venenentzündungen, Herpes oder äußerlichen Hämorrhoiden Use of marmot oil for the treatment of acne vulgaris, acne rosacea, phlebitis, herpes or external hemorrhoids |
| 06/18/2009 | CA2709104A1 Method and composition for treating a serotonin receptor-mediated condition |
| 06/18/2009 | CA2708570A1 Organic compounds |
| 06/18/2009 | CA2708303A1 Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| 06/18/2009 | CA2707047A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 06/18/2009 | CA2705921A1 Dual-acting benzoimidazole derivatives and their use as antihypertensive agents |
| 06/17/2009 | EP2071040A2 Diagnostics and therapeutics for vascular disease |
| 06/17/2009 | EP2071036A2 Methods for identifying RNA-binding compounds |
| 06/17/2009 | EP2070944A1 Specific binding agents of human angiopoietin-2 |
| 06/17/2009 | EP2070930A1 Polycycloalkylpurines as adenosine receptor antagonists |
| 06/17/2009 | EP2070927A1 Fused heterocyclic derivative |
| 06/17/2009 | EP2070921A1 Indolylmaleimide derivatives as protein kinase c inhibitors |
| 06/17/2009 | EP2070919A1 Spiroquinone compound and pharmaceutical composition |
| 06/17/2009 | EP2070914A1 New antagonist derivatives of the vitronectin receiver, method for preparing same, application of same as medicine and pharmaceutical compositions containing them |
| 06/17/2009 | EP2070529A1 Medical use of 3-(2,2,2-trimethylhydrazinium) propionate orotate |
| 06/17/2009 | EP2069388A2 Peptides derived from the c2 domain of epsilon pkc, and use thereof |
| 06/17/2009 | EP2069365A1 Novel 5,7-disubstituted [1, 3]thiazolo [4, 5d]pyrimidin-2 (3h)-amine derivatives and their use in therapy |
| 06/17/2009 | EP2069364A1 Novel 5, 7-disubstituted [1, 3]thiazolo [4, 5-d]pyrimidin-2 (3h)-one derivatives and their use in therapy |
| 06/17/2009 | EP2069360A2 Polymorphic forms of spirapril hydrochloride |
| 06/17/2009 | EP2069336A1 Pyridin-4-yl derivatives as immunomodulating agents |
| 06/17/2009 | EP2069335A1 Pyridin-3-yl derivatives as immunomodulating agents |
| 06/17/2009 | EP2069319A1 Cyclic sulfones useful as mitochondrial sodium-calcium exchangers |
| 06/17/2009 | EP2069294A1 Soluble epoxide hydrolase inhibitors |
| 06/17/2009 | EP2068941A2 Improvement of arginase levels/activity |
| 06/17/2009 | EP2068910A2 Use of exendins and exendin agonists and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition |
| 06/17/2009 | EP2068902A2 Tea-derived compostiions and methods of using same for cardiovascular health |
| 06/17/2009 | EP2068893A2 Liquid chalcogenide compositions and methods of manufacturing and using the same |
| 06/17/2009 | EP2068891A2 Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| 06/17/2009 | EP2068879A2 Pyrroloquinoline quinone drugs and methods of use thereof |
| 06/17/2009 | EP2068878A2 Rho kinase inhibitors |
| 06/17/2009 | EP2068861A2 Compositions comprising omega-3 fatty acids, and their use in treating peripheral artery disease and intermittent claudication |
| 06/17/2009 | EP2068857A2 Soluble epoxide hydrolase inhibitors |
| 06/17/2009 | EP2068850A1 Use of a2a adenosine receptor agonists in the treatment of ischemia |
| 06/17/2009 | EP2068628A2 Method of treating a condition associated with phosphorylation of task-1 |
| 06/17/2009 | EP2011497A4 Agent exhibiting a neurotropic, neuromodulator, cerebrovascular and anti- stroke activity |
| 06/17/2009 | EP1735320B1 Compounds and methods for treating dyslipidemia |
| 06/17/2009 | EP1485381B1 Azolylaminoazine as inhibitors of protein kinases |
| 06/17/2009 | EP1485375B1 Pyrimidine compounds |
| 06/17/2009 | EP1472230B1 Ansamycins having improved pharmacological and biological properties |
| 06/17/2009 | EP1465652A4 Povidone-containing carriers for polypeptide growth factors |
| 06/17/2009 | EP1435957B1 Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes |
| 06/17/2009 | EP1390378B1 Pharmaceutically active uridine esters |